# US 2024/0174996 A1 · Method for site-specific conjugation of nucleic acid to crispr family protein, and conjugate thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174996 A1
- Document ID: US20240174996A1
- Status: Published application
- Kind: A1
- Application number: 17/775,482
- Filed: 2020-11-11
- Published: 2024-05-30
- Earliest claimed: 2019-11-11
- Assignees: Beijing Huida Biotechnology Co., Ltd
- Applicants: Beijing Huida Biotechnology Co., Ltd
- Inventors: Tao LIU; Xinyu LING; Xiaoqin GAO
- Web page: https://patentgrep.com/patent/US20240174996A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/3513: Protein; Peptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for site-specific conjugation of nucleic acid to a CRISPR family protein, and a conjugate thereof and the use thereof. The site-specific conjugation method comprises: mutating a CRISPR family protein site-specifically with an unnatural amino acid, and then conjugating a nucleic acid to the mutated CRISPR family protein, wherein the unnatural amino acid has orthogonal chemical reactivity. The CRISPR family protein site-specifically mutated and the conjugate thereof of the present application can be used to improve gene cutting, gene editing efficiency and base editing efficiency, etc.

## Claims

### Claim 1

A method for site-specific conjugation of a nucleic acid to a CRISPR family protein, comprising:
(a) mutating the CRISPR family protein site-specifically with an unnatural amino acid; and
(b) conjugating the nucleic acid to the CRISPR family protein site-specifically mutated by the unnatural amino acid obtained in step (a), thereby obtaining a site-specific nucleic acid conjugate of the CRISPR family protein;
wherein the unnatural amino acid has orthogonal chemical reactivity.

### Claim 2 (depends on 1)

The method for site-specific conjugation of claim 1, wherein the CRISPR family protein comprises, but is not limited to, Cas9 protein, Cas12a protein, CasX protein, Cas ϕ protein, Cas12g protein from different species or genera, or a related inactivated counterpart thereof having no cleavage activity but retaining binding activity.

### Claim 3 (depends on 1)

The method for site-specific conjugation of claim 1, wherein the orthogonal chemical reactivity means, but is not limited to, that the unnatural amino acid comprises an azido, an alkynyl, a cyclopropenyl or a tetrazine group.

### Claim 4

A CRISPR family protein site-specifically mutated by an unnatural amino acid, wherein the unnatural amino acid bears an azido, an alkynyl, a cyclopropenyl or a tetrazine group; the CRISPR family protein comprises, but is not limited to, Cas9 protein, Cas12a protein, CasX protein, Cas ϕ protein, Cas12g protein from different species or genera, or a related inactivated counterpart thereof having no cleavage activity but retaining binding activity.

### Claim 5 (depends on 4)

The CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, wherein the CRISPR family protein is SpCas9 mutated at one or more of: positions K3, D39, H41, H116, D576, E945, K1151 and G1367 of SEQ ID NO.1.

### Claim 6 (depends on 4)

The CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, wherein the CRISPR family protein is AsCas12a mutated at one or more of: positions M806, L834, S835, K860, K1086 of SEQ ID NO.3

### Claim 7 (depends on 4)

The CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, wherein the unnatural amino acid is selected from one of the following compounds:

### Claim 8 (depends on 4)

A method for preparing the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, comprising the steps of:
(1) site selection: based on structural information of the CRISPR family protein, selecting one or more specific amino acid sites in the amino acid sequence of the CRISPR family protein;
(2) genetic mutagenesis: mutating the codon encoding the amino acid at the site selected in step (1) to codon TAG by a genetic engineering method, to obtain a mutated CRISPR protein gene;
(3) construction of a mutant expression vector: ligating the mutated CRISPR protein gene obtained by genetic engineering in step (2) to an expression plasmid by means of molecular cloning, to obtain an expression vector plasmid comprising a mutant sequence; and
(4) protein expression: co-transfecting the expression vector plasmid obtained in (3) and a tool plasmid for unnatural amino acid insertion, into the same host cell, culturing the host cell successfully transfected in a culture solution supplemented with an unnatural amino acid, and inducing the expression of the mutated protein in the host cell.

### Claim 9 (depends on 8)

The method for preparing the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 8, wherein the tool plasmid for unnatural amino acid insertion encodes tRNA and aminoacyl-tRNA synthetase, which specifically recognizes TAG codon and inserts, at the position corresponding to the codon, the unnatural amino acid.

### Claim 10 (depends on 4)

A nucleic acid sequence encoding the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, wherein the codon corresponding to the unnatural amino acid in the base sequence of the nucleic acid is TAG, TAA or TGA.

### Claim 11 (depends on 4)

A vector for preparing the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, comprising a corresponding nucleic acid sequence encoding the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4.

### Claim 12 (depends on 4)

A site-specific nucleic acid conjugate of a CRISPR family protein, wherein the CRISPR family protein is the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4.

### Claim 13 (depends on 12)

The site-specific nucleic acid conjugate of a CRISPR family protein of claim 12, wherein the nucleic acid is an oligo DNA, a donor DNA, a crRNA, and a related modified nucleic acid thereof.

### Claim 14 (depends on 4)

Use of the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4 or the site-specific nucleic acid conjugate thereof in improving gene editing efficiency and/or reducing off-target effect.

### Claim 15 (depends on 1)

The method for site-specific conjugation of claim 1, wherein the related inactivated counterpart is dCas9 protein, dCas12a protein, or ddCas12a protein.

### Claim 16 (depends on 4)

The CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 4, wherein the related inactivated counterpart is dCas9 protein, dCas12a protein, or ddCas12a protein.

### Claim 17 (depends on 7)

The CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 7, wherein the unnatural amino acid is pAcF, AeF, PrpF, NAEK or TetF.

### Claim 18 (depends on 8)

The method for preparing the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 8, wherein the CRISPR family protein is SpCas9 or AsCas12a.

### Claim 19 (depends on 8)

The method for preparing the CRISPR family protein site-specifically mutated by an unnatural amino acid of claim 8, wherein the unnatural amino acid is pAcF, AeF, NAEK or another unnatural amino acid.

### Claim 20 (depends on 10)

The nucleic acid sequence of claim 10, wherein the codon corresponding to the unnatural amino acid in the base sequence of the nucleic acid is TAG.
